Stockscreener 앱 받기
2.47
0.82%
0.02
시간 외 거래:
2.49
0.02
+0.81%
Eledon Pharmaceuticals Inc 주식(ELDN)의 최신 뉴스
Will Eledon Pharmaceuticals Inc. stock deliver shareholder valueWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
What’s the beta of Eledon Pharmaceuticals Inc. stock2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Can Eledon Pharmaceuticals Inc. expand its profit marginsGap Down & Free High Return Stock Watch Alerts - mfd.ru
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference - MarketBeat
Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path By Investing.com - Investing.com Canada
What makes Eledon Pharmaceuticals Inc. stock attractive todayJuly 2025 Decliners & Real-Time Volume Analysis Alerts - mfd.ru
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - Sahm
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Biotech outlook talk: Eledon Pharma fireside chat at Guggenheim - Stock Titan
Eledon Pharmaceuticals (NASDAQ:ELDN) Shares Up 3.6% – Should You Buy? - Defense World
Eledon Pharmaceuticals: Sustained Tegoprubart Efficacy, Differentiated Safety, and Upcoming Transplant Catalysts Support Buy Rating - TipRanks
Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium - Sahm
Eledon reports positive 24-month kidney transplant data for tegoprubart By Investing.com - Investing.com India
Eledon Pharmaceuticals restructures stake via pre-funded warrant - MSN
Craig-Hallum Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating - 富途资讯
Eledon Pharmaceuticals Presents Long-Term Phase 1B Data for Tegoprubart in Kidney Transplant Patients At the American Society of Transplant Surgeons Winter Symposium - marketscreener.com
Eledon Pharmaceuticals (ELDN) to Reveal Promising Kidney Transpl - GuruFocus
Eledon reports positive 24-month kidney transplant data for tegoprubart - Investing.com
2-year transplant data: Eledon's tegoprubart shows no rejection in 8 patients - stocktitan.net
Surprises Report: Is SDHC stock a value trapEarnings Overview Summary & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Loss Report: Is Eledon Pharmaceuticals Inc stock a good dividend stock2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Growth Value: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingOil Prices & Safe Entry Zone Identification - baoquankhu1.vn
Midday Stock Roundup: loanDepot Jumps on Trump’s Proposed Mortgage Plan - Orange County Business Journal
Do Not Use - ocbj.com
What Caused Eledon Pharmaceuticals Stock (ELDN) to Drop 50% Today? - Intellectia AI
Patterns Watch: Is AVAH forming a double bottomWeekly Trend Recap & Smart Investment Allocation Tips - baoquankhu1.vn
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives $9.67 Average Price Target from Analysts - Defense World
Buy Signal: Will Eledon Pharmaceuticals Inc stock deliver better than expected guidanceJuly 2025 Drop Watch & Low Risk High Reward Trade Ideas - Bộ Nội Vụ
Midday Stock Roundup: Staar Down 4% on Board Changes - Orange County Business Journal
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Eledon Pharmaceuticals Shares Sink After Announcing $50 Million Public Offering - MSN
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook - The Manila Times
Profit Review: Can Eledon Pharmaceuticals Inc. stock sustain market leadershipQuarterly Portfolio Report & Stepwise Swing Trade Plans - ulpravda.ru
Can Eledon Pharmaceuticals Inc. stock sustain market leadershipJuly 2025 Retail & Risk Adjusted Buy and Sell Alerts - Улправда
How Eledon Pharmaceuticals Inc. (2TK) stock trades after earningsQuarterly Earnings Report & Community Verified Trade Signals - ulpravda.ru
Eledon’s tegoprubart shows promise in kidney transplantation trials By Investing.com - Investing.com South Africa
Eledon’s tegoprubart shows promise in kidney transplantation trials - Investing.com
Can Eledon Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Update & Verified Entry Point Signals - Улправда
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3%Time to Buy? - MarketBeat
Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Up 3% – Time to Buy? - Defense World
Is Eledon Pharmaceuticals Inc. (2TK) stock a defensive play amid uncertaintyCandlestick Pattern Analysis & Free Expert Stock Watchlists - ulpravda.ru
Cash per share of Eledon Pharmaceuticals, Inc. – MUN:2TK - TradingView — Track All Markets
Midday Stock Roundup: Lantronix Stock up 4.8% Today - Orange County Business Journal
Eledon Pharmaceuticals Restructures Stake via Pre-Funded Warrant - TipRanks
Midday Stock Roundup: Rivian Down on Production Totals - Orange County Business Journal
1.52%
1.68%
자본화:
|
볼륨(24시간):